Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain - Pipeline Review, H2 2017, provides an overview of the Dental Pain (Central Nervous System) pipeline landscape.
A pain in the tooth is called dental pain. This can be caused by tooth decay, damaged filling, tooth fracture, etc. Symptoms of a toothache may include: tooth pain that may be sharp, throbbing, or constant. In some people, pain results only when pressure is applied to the tooth. Swelling around the tooth, fever or headache and foul-tasting drainage from the infected tooth occurs. Treatment for a toothache depends on the cause.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dental Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dental Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dental Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dental Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively.
Dental Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dental Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dental Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dental Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dental Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dental Pain (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dental Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dental Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Laboratorios Del Dr Esteve SA
Pacira Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dental Pain - Overview
Dental Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Dental Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dental Pain - Companies Involved in Therapeutics Development
Laboratorios Del Dr Esteve SA
Pacira Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd
Dental Pain - Drug Profiles
(celecoxib + tramadol hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AFAP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bupivacaine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
funapide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dental Pain - Dormant Projects
Dental Pain - Discontinued Products
Dental Pain - Product Development Milestones
Featured News & Press Releases
Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac
Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dental Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Dental Pain - Pipeline by Laboratorios Del Dr Esteve SA, H2 2017
Dental Pain - Pipeline by Pacira Pharmaceuticals Inc, H2 2017
Dental Pain - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Dental Pain - Dormant Projects, H2 2017
Dental Pain - Dormant Projects, H2 2017 (Contd..1), H2 2017
Dental Pain - Discontinued Products, H2 2017
List of Figures
Number of Products under Development for Dental Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017